GIP and obesity due to melanocortin 4 receptor deficiency: As a result, these latest generation of anti-obesity medications (AOMs) with GLP1RAs and GIP/GLP1RAs represent the fastest growth in prescribing of all pharmaceuticals and represent a landmark change in the approach to obesity treatment [5,6].